Our mission is to improve the quality of life and life expectancy of people living with cancer and cancer-related diseases.
Ascelia Pharma focuses on differentiated, underappreciated and de-risked product candidates addressing unmet medical needs.
Two drug candidates in clinical stage
2015: Initiation of investigator initiated phase 1 study on Oncoral
2015: US Orphan Drug Designation for Mangoral revised to "use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where the use of gadolinium based contrast agents cannot be administrered".